This course has expired. View available courses.
Endocrinology
GLP1-RAs and their place in the new T2D treatment algorithm – ACRRM
The introduction of new treatments in diabetes, including injectable non-insulin glycemic modulators, creates new opportunities. The position of GLP1-RA agents in current Australian diabetes treatment algorithms requires GPs to re-think traditional models, including the role of these agents in combination with metformin or as an adjunct to other established treatments. This program is supported by […]
DURATION
2 hr
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
ACRRM
EXPIRY DATE
2022-09-07
The introduction of new treatments in diabetes, including injectable non-insulin glycemic modulators, creates new opportunities.
The position of GLP1-RA agents in current Australian diabetes treatment algorithms requires GPs to re-think traditional models, including the role of these agents in combination with metformin or as an adjunct to other established treatments.
This program is supported by an independent educational grant provided from Eli Lilly.
Faculty
Dr Marwan Obaid (Endocrinologist)
MBBS BSc(Med) FRACP MMed
A/Prof Gary Kilov (GP)
MBBCh
Launceston, TAS
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Individualising injectable therapy for patients with Type 2 diabetes
- Evaluate the efficacy and safety of GLP 1 receptor agonists compared to insulin
- Identify advantages of GLP1-RAs in specific patient groups compared to oral glucose-lowering medicines or insulin
Accreditation
This PDP Activity is accredited by The Australian College of Rural & Remote Medicine for 1 hour of Educational Activity and 1 hour of Performance Review.
ACRRM ID: 24948